> This is the maddening influence of capitalism and intellectual property law on anti-aging science. The most promising avenue for rejuvenation (IMO) is not attracting research attention because it cannot attract venture capital; it can’t attract venture capital because there is no attractive business model; and there is no business model because of the structure of our patent law.
This is common in pharma patent law. At an earlier company we made some progress on a treatment for a fairly common disease, but it looked like any compounding pharmacy could make it. So we abandoned that path and went in a different direction that was protectable (and more effective, true). The inverse is the case as well: had the less effective treatment been available, it might not have been worth developing something that could help even more people, because those that needed the better treatment would not be enough to justify development.
But the situation is not as clear as stated by the author. First of all, much of the work is basic research, and that is mostly funded by governments and charities. Second of all, even if you've identified a mechanism of action, developing a feasible in vivo way to trigger that action, figuring out how to manufacture it at scale, and getting it approved can provide many patent opportunities. When people complain "why are drugs expensive when the government pays for it" they miss the point: "government" developed the transistor,* it was private companies that developed the IC and the microprocessor. The situation with drugs is analogous.
* Yes the transistor was invented at Bell Labs, but Bell Labs only existed due to the structure of the government's consent decree for the Bell telephone company, and when that decree was lifted Bell Labs suffered a precipitous decline. Anyway, it's just an analogy.